Search
LENSAR Inc
LNSRAdd to Watchlist
5.540USD
-0.290-4.97%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
67.06MMarket Cap
2.27P/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D
Today
-4.97%
5 Days
-1.77%
1 Month
-4.48%
6 Months
-45.20%
Year to Date
-52.36%
1 Year
-60.74%
TradingKey Stock Score of LENSAR Inc
Currency: USD Updated: 2026-05-15Key Insights
LENSAR Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 78 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 8.50.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
LENSAR Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
LENSAR Inc Highlights
StrengthsRisks
LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. Its product portfolio includes the LENSAR Laser System (LLS), and the ALLY Robotic Cataract Laser Treatment System (ALLY). The Company has developed its ALLY Robotic Cataract Laser System as a compact, ergonomic system utilizing a fast dual-modality laser and integrating artificial intelligence (AI) into proprietary imaging and software. ALLY is designed to transform cataract surgery by utilizing the Company’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes its proprietary Streamline software technology, designed to guide surgeons to achieve better outcomes.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 52.17% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 64.16M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 64.16M.
Overvalued
The company’s latest PE is 2.27, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 6.68M shares, decreasing 4.88% quarter-over-quarter.
Held by Brandes Investmen
Star Investor Brandes Investmen holds 856.22K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.08.
Analyst Rating
Based on
2
analysts
Strong Buy
Current Rating
8.500
Target Price
+45.80%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
LENSAR Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
LENSAR Inc Info
LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. Its product portfolio includes the LENSAR Laser System (LLS), and the ALLY Robotic Cataract Laser Treatment System (ALLY). The Company has developed its ALLY Robotic Cataract Laser System as a compact, ergonomic system utilizing a fast dual-modality laser and integrating artificial intelligence (AI) into proprietary imaging and software. ALLY is designed to transform cataract surgery by utilizing the Company’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes its proprietary Streamline software technology, designed to guide surgeons to achieve better outcomes.
Ticker SymbolLNSR
CompanyLENSAR Inc
CEOCurtis (Nicholas T)
Websitehttps://www.lensar.com/
Related Instruments
-1.32%
-2.23%
-1.62%
-0.49%
-1.30%
+0.41%
-1.57%
-1.05%
-2.22%
-1.04%
-1.59%
-3.29%
-1.06%
-6.97%
+0.04%
-0.76%
-0.71%
+1.31%
-1.21%
-0.56%Popular Instruments
102.160
+3.297 (+3.33%)
300.230
+2.020 (+0.68%)
225.320
-10.420 (-4.42%)
4538.710
-111.520 (-2.40%)
482.020
-7.101 (-1.45%)
1407.610
+24.890 (+1.80%)
724.660
-51.350 (-6.62%)
396.780
-4.290 (-1.07%)
78023.420
-207.580 (-0.27%)
422.240
-21.060 (-4.75%)
